Telehealth Multi-Component Optional Model (MOM) Study
Launched by UNIVERSITY OF ARKANSAS · Oct 17, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Telehealth Multi-Component Optional Model (MOM) Study is looking at how to best provide postpartum care for new mothers. Researchers want to compare two different ways of delivering this care: one using telehealth services where healthcare providers connect with patients online (called Telehealth MOM) and another that enhances the usual in-person care (called enhanced standard of care, or ESoC). This study is especially focused on understanding the needs of diverse women, including those from racial and rural communities, to make sure they receive the support they need after giving birth.
To participate in this study, women need to be between 18 and 44 years old and pregnant between 16 to 35 weeks. They can have had either a vaginal birth or a cesarean section. However, some women with specific health conditions, like certain types of diabetes or heart disease, won't be eligible to join. Participants can expect to receive care through one of the two models being studied and will help researchers learn more about how to improve postpartum care for all women. If you're interested in joining, this could be a great opportunity to contribute to important healthcare research!
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women between 16-35 weeks gestation
- • Age 18-44 years
- • Ability to speak English, Spanish, or Marshallese
- • Participants may have either a vaginal birth or cesarean section birth
- Exclusion Criteria:
- • Type 1 diabetes on an insulin pump followed closely by endocrinology
- • Uncontrolled Type 2 diabetes
- • End stage renal disease followed closely by nephrology
- • ICU admission at any point during pregnancy or delivery hospitalization
- • Other maternal conditions requiring additional surgeries (i.e. cesarean hysterectomy or intrapartum or postpartum oophorectomy/appendectomy)
- • Incarceration
- • Mental disability limiting decision-making capacity
- • Uncontrolled chronic hypertension
- • HELLP syndrome during pregnancy
- • Sickle cell disease
- • Maternal heart condition or heart disease
- • Opioid use disorder
- • Lupus
- • Thrombophilia or blood clots
- • Need for blood transfusion during delivery hospitalization
- • Other maternal conditions or complications, known during pregnancy or delivery hospitalization, requiring prolonged hospitalization postpartum
About University Of Arkansas
The University of Arkansas is a leading research institution dedicated to advancing healthcare through innovative clinical trials. With a commitment to excellence in research and education, the university facilitates a collaborative environment that encourages interdisciplinary studies and the development of cutting-edge therapies. Its clinical trial programs leverage state-of-the-art facilities and expert faculty, aiming to improve patient outcomes and contribute to the body of medical knowledge. The university fosters partnerships with healthcare providers and industry stakeholders, ensuring rigorous ethical standards and adherence to regulatory requirements in all research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
El Dorado, Arkansas, United States
Fayetteville, Arkansas, United States
Fort Smith, Arkansas, United States
Jonesboro, Arkansas, United States
Little Rock, Arkansas, United States
Springdale, Arkansas, United States
Patients applied
Trial Officials
Jennifer Callaghan-Koru, PhD
Principal Investigator
University of Arkansas
Pearl McElfish, PhD
Principal Investigator
University of Arkansas
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported